Table 3. Open in new tab Univariable...

	Durability postexposure	Durability postescalation
Proactive vs reactive	0.50 (0.31, 0.78)	.003	0.54 (0.34, 0.85)	.008
Male vs Female	1.18 (0.76, 1.83)	.474	1.12 (0.72, 1.74)	.611
Age at time of induction	0.99 (0.98, 1.01)	.396	0.99 (0.98, 1.01)	.328
Weight at time of escalation	0.99 (0.99, 1.01)	.845	1.00 (0.99, 1.01)	.620
Disease duration	0.99 (0.96, 1.01)	.302	0.99 (0.96, 1.01)	.268
Montreal classification—age at onset
A1 < 16 years	Ref		Ref
A2 – 17-40 years	0.97 (0.58, 1.62)	.904	0.95 (0.57, 1.59)	.837
A3 > 40 years	1.09 (0.46, 2.58)	.853	0.78 (0.33, 1.84)	.564
Montreal classification—disease location
L1—ileal	Ref		Ref
L2—colonic	0.54 (0.28, 1.04)	.066	0.65 (0.33, 1.25)	.192
L3—ileocolonic	0.55 (0.30, 0.99)	.046	0.63 (0.35, 1.13)	.122
L4—isolated upper GI	0.32 (0.04, 2.45)	.273	0.53 (0.07, 4.03)	.540
Montreal classification—disease behavior
B1—uncomplicated	Ref		Ref
B2—stricturing	0.88 (0.51, 1.51)	.643	0.80 (0.46, 1.37)	.409
B3—penetrating	0.96 (0.56, 1.62)	.867	0.92 (0.54, 1.57)	.762
Perianal disease	0.50 (0.32, 0.79)	.003	0.45 (0.29, 0.70)	<.001
Prior surgery	1.20 (0.77, 1.86)	.423	1.25 (0.80, 1.95)	.319
Current smoker	1.19 (0.69, 2.07)	.529	1.14 (0.66, 1.97)	.639
Tumor Necrosis Factor Naïve	0.76 (0.48, 1.21)	.245	0.74 (0.47, 1.17)	.199
Infliximab vs adalimumab escalation	0.81 (0.52, 1.26)	.355	0.87 (0.56, 1.35)	.537
Concurrent immunomodulator use	0.73 (0.47, 1.15)	.173	0.72 (0.46, 1.12)	.143

Durability postexposure

Durability postescalation

HR (95% CI)

P-value

HR (95% CI)

P-value

Proactive vs reactive

0.50 (0.31, 0.78)

.003

0.54 (0.34, 0.85)

.008

Male vs Female

1.18 (0.76, 1.83)

.474

1.12 (0.72, 1.74)

.611

Age at time of induction

0.99 (0.98, 1.01)

.396

0.99 (0.98, 1.01)

.328

Weight at time of escalation

0.99 (0.99, 1.01)

.845

1.00 (0.99, 1.01)

.620

Disease duration

0.99 (0.96, 1.01)

.302

0.99 (0.96, 1.01)

.268

Montreal classification—age at onset

A1 < 16 years

Ref

A2 – 17-40 years

0.97 (0.58, 1.62)

.904

0.95 (0.57, 1.59)

.837

A3 > 40 years

1.09 (0.46, 2.58)

.853

0.78 (0.33, 1.84)

.564

Montreal classification—disease location

L1—ileal

Ref

L2—colonic

0.54 (0.28, 1.04)

.066

0.65 (0.33, 1.25)

.192

L3—ileocolonic

0.55 (0.30, 0.99)

.046

0.63 (0.35, 1.13)

.122

L4—isolated upper GI

0.32 (0.04, 2.45)

.273

0.53 (0.07, 4.03)

.540

Montreal classification—disease behavior

B1—uncomplicated

Ref

B2—stricturing

0.88 (0.51, 1.51)

.643

0.80 (0.46, 1.37)

.409

B3—penetrating

0.96 (0.56, 1.62)

.867

0.92 (0.54, 1.57)

.762

Perianal disease

0.50 (0.32, 0.79)

.003

0.45 (0.29, 0.70)

<.001

Prior surgery

1.20 (0.77, 1.86)

.423

1.25 (0.80, 1.95)

.319

Current smoker

1.19 (0.69, 2.07)

.529

1.14 (0.66, 1.97)

.639

Tumor Necrosis Factor Naïve

0.76 (0.48, 1.21)

.245

0.74 (0.47, 1.17)

.199

Infliximab vs adalimumab escalation

0.81 (0.52, 1.26)

.355

0.87 (0.56, 1.35)

.537

Concurrent immunomodulator use

0.73 (0.47, 1.15)

.173

0.72 (0.46, 1.12)

.143

	Durability postexposure	Durability postescalation
Proactive vs reactive	0.50 (0.31, 0.78)	.003	0.54 (0.34, 0.85)	.008
Male vs Female	1.18 (0.76, 1.83)	.474	1.12 (0.72, 1.74)	.611
Age at time of induction	0.99 (0.98, 1.01)	.396	0.99 (0.98, 1.01)	.328
Weight at time of escalation	0.99 (0.99, 1.01)	.845	1.00 (0.99, 1.01)	.620
Disease duration	0.99 (0.96, 1.01)	.302	0.99 (0.96, 1.01)	.268
Montreal classification—age at onset
A1 < 16 years	Ref		Ref
A2 – 17-40 years	0.97 (0.58, 1.62)	.904	0.95 (0.57, 1.59)	.837
A3 > 40 years	1.09 (0.46, 2.58)	.853	0.78 (0.33, 1.84)	.564
Montreal classification—disease location
L1—ileal	Ref		Ref
L2—colonic	0.54 (0.28, 1.04)	.066	0.65 (0.33, 1.25)	.192
L3—ileocolonic	0.55 (0.30, 0.99)	.046	0.63 (0.35, 1.13)	.122
L4—isolated upper GI	0.32 (0.04, 2.45)	.273	0.53 (0.07, 4.03)	.540
Montreal classification—disease behavior
B1—uncomplicated	Ref		Ref
B2—stricturing	0.88 (0.51, 1.51)	.643	0.80 (0.46, 1.37)	.409
B3—penetrating	0.96 (0.56, 1.62)	.867	0.92 (0.54, 1.57)	.762
Perianal disease	0.50 (0.32, 0.79)	.003	0.45 (0.29, 0.70)	<.001
Prior surgery	1.20 (0.77, 1.86)	.423	1.25 (0.80, 1.95)	.319
Current smoker	1.19 (0.69, 2.07)	.529	1.14 (0.66, 1.97)	.639
Tumor Necrosis Factor Naïve	0.76 (0.48, 1.21)	.245	0.74 (0.47, 1.17)	.199
Infliximab vs adalimumab escalation	0.81 (0.52, 1.26)	.355	0.87 (0.56, 1.35)	.537
Concurrent immunomodulator use	0.73 (0.47, 1.15)	.173	0.72 (0.46, 1.12)	.143

Table 3.

Open in new tab

Univariable analysis comparing durability post exposure and durability postescalation.

	Durability postexposure		Durability postescalation
	HR (95% CI)	P-value	HR (95% CI)	P-value
Proactive vs reactive	0.50 (0.31, 0.78)	.003	0.54 (0.34, 0.85)	.008
Male vs Female	1.18 (0.76, 1.83)	.474	1.12 (0.72, 1.74)	.611
Age at time of induction	0.99 (0.98, 1.01)	.396	0.99 (0.98, 1.01)	.328
Weight at time of escalation	0.99 (0.99, 1.01)	.845	1.00 (0.99, 1.01)	.620
Disease duration	0.99 (0.96, 1.01)	.302	0.99 (0.96, 1.01)	.268
Montreal classification—age at onset
A1 < 16 years	Ref		Ref
A2 – 17-40 years	0.97 (0.58, 1.62)	.904	0.95 (0.57, 1.59)	.837
A3 > 40 years	1.09 (0.46, 2.58)	.853	0.78 (0.33, 1.84)	.564
Montreal classification—disease location
L1—ileal	Ref		Ref
L2—colonic	0.54 (0.28, 1.04)	.066	0.65 (0.33, 1.25)	.192
L3—ileocolonic	0.55 (0.30, 0.99)	.046	0.63 (0.35, 1.13)	.122
L4—isolated upper GI	0.32 (0.04, 2.45)	.273	0.53 (0.07, 4.03)	.540
Montreal classification—disease behavior
B1—uncomplicated	Ref		Ref
B2—stricturing	0.88 (0.51, 1.51)	.643	0.80 (0.46, 1.37)	.409
B3—penetrating	0.96 (0.56, 1.62)	.867	0.92 (0.54, 1.57)	.762
Perianal disease	0.50 (0.32, 0.79)	.003	0.45 (0.29, 0.70)	<.001
Prior surgery	1.20 (0.77, 1.86)	.423	1.25 (0.80, 1.95)	.319
Current smoker	1.19 (0.69, 2.07)	.529	1.14 (0.66, 1.97)	.639
Tumor Necrosis Factor Naïve	0.76 (0.48, 1.21)	.245	0.74 (0.47, 1.17)	.199
Infliximab vs adalimumab escalation	0.81 (0.52, 1.26)	.355	0.87 (0.56, 1.35)	.537
Concurrent immunomodulator use	0.73 (0.47, 1.15)	.173	0.72 (0.46, 1.12)	.143

	Durability postexposure		Durability postescalation
	HR (95% CI)	P-value	HR (95% CI)	P-value
Proactive vs reactive	0.50 (0.31, 0.78)	.003	0.54 (0.34, 0.85)	.008
Male vs Female	1.18 (0.76, 1.83)	.474	1.12 (0.72, 1.74)	.611
Age at time of induction	0.99 (0.98, 1.01)	.396	0.99 (0.98, 1.01)	.328
Weight at time of escalation	0.99 (0.99, 1.01)	.845	1.00 (0.99, 1.01)	.620
Disease duration	0.99 (0.96, 1.01)	.302	0.99 (0.96, 1.01)	.268
Montreal classification—age at onset
A1 < 16 years	Ref		Ref
A2 – 17-40 years	0.97 (0.58, 1.62)	.904	0.95 (0.57, 1.59)	.837
A3 > 40 years	1.09 (0.46, 2.58)	.853	0.78 (0.33, 1.84)	.564
Montreal classification—disease location
L1—ileal	Ref		Ref
L2—colonic	0.54 (0.28, 1.04)	.066	0.65 (0.33, 1.25)	.192
L3—ileocolonic	0.55 (0.30, 0.99)	.046	0.63 (0.35, 1.13)	.122
L4—isolated upper GI	0.32 (0.04, 2.45)	.273	0.53 (0.07, 4.03)	.540
Montreal classification—disease behavior
B1—uncomplicated	Ref		Ref
B2—stricturing	0.88 (0.51, 1.51)	.643	0.80 (0.46, 1.37)	.409
B3—penetrating	0.96 (0.56, 1.62)	.867	0.92 (0.54, 1.57)	.762
Perianal disease	0.50 (0.32, 0.79)	.003	0.45 (0.29, 0.70)	<.001
Prior surgery	1.20 (0.77, 1.86)	.423	1.25 (0.80, 1.95)	.319
Current smoker	1.19 (0.69, 2.07)	.529	1.14 (0.66, 1.97)	.639
Tumor Necrosis Factor Naïve	0.76 (0.48, 1.21)	.245	0.74 (0.47, 1.17)	.199
Infliximab vs adalimumab escalation	0.81 (0.52, 1.26)	.355	0.87 (0.56, 1.35)	.537
Concurrent immunomodulator use	0.73 (0.47, 1.15)	.173	0.72 (0.46, 1.12)	.143

This Feature Is Available To Subscribers Only